Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Way S Lee

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Pediatric Gastroenterology and Nutrition|October 30, 2015
Should Partial Hydrolysates Be Used as Starter Infant Formula? A Working Group ConsensusYvan Vandenplas, Pedro Alarcon, David Fleischer, et al.
Nature Genetics|February 28, 2018
Human TGF-β1 deficiency causes severe inflammatory bowel disease and encephalopathyDaniel Kotlarz, Benjamin Marquardt, Tuva Barøy, et al.
The Lancet. Gastroenterology & Hepatology|April 26, 2024
Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trialNadia Ovchinsky, Madeleine Aumar, Alastair Baker, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Pediatric Gastroenterology and Nutrition|October 30, 2015
Should Partial Hydrolysates Be Used as Starter Infant Formula? A Working Group ConsensusYvan Vandenplas, Pedro Alarcon, David Fleischer, et al.
Nature Genetics|February 28, 2018
Human TGF-β1 deficiency causes severe inflammatory bowel disease and encephalopathyDaniel Kotlarz, Benjamin Marquardt, Tuva Barøy, et al.
The Lancet. Gastroenterology & Hepatology|April 26, 2024
Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trialNadia Ovchinsky, Madeleine Aumar, Alastair Baker, et al.
Pageof 2